To assess the anabolic properties of key plant based protein sources and specific protein blends
ID
Source
Brief title
Condition
- Other condition
Synonym
Health condition
This study will evaluate the skeletal muscle anabolic response to protein consumption
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Primary study parameters include muscle protein synthesis rates based on mixed
muscle and myofibrilar protein bound [U-13C6]-phenylalanine enrichments.
Secondary outcome
Secondary endpoints will include plasma amino acid, glucose and insulin
concentrations as well as whole-body protein synthesis, breakdown, oxidation,
and net balance.
Background summary
More than half of the total amount of dietary protein that is consumed by
humans worldwide is of plant origin, with plant based proteins providing up to
80% of dietary protein consumed in less developed regions. Overall it is
assumed that plant based proteins are less potent in stimulating post-prandial
muscle protein synthesis. However, the anabolic properties of the main plant
based protein sources have hardly been assessed. This project will investigate
the anabolic properties of a selection of plant based protein sources and a key
reference protein.
Study objective
To assess the anabolic properties of key plant based protein sources and
specific protein blends
Study design
Parallel group, randomized, double blind.
Intervention
The post-prandial muscle protein synthetic response after ingestion of plant
based protein drinks and a key reference protein.
Study burden and risks
The burden and risks involved in participating in this experiment are small.
Insertion of the catheters in a vein is comparable to a normal blood draw and
the only risk is a small local hematoma. Muscle biopsies will be obtained under
local anaesthesia by an experienced physician, but may cause some minor
discomfort. The discomfort is comparable to muscle soreness or the pain one has
after bumping into the corner of a table. During the experimental trial 16
blood samples (170mL total) will be obtained. The total amount of blood
collected is less than half the amount of a blood donation and will be
completely restored in approximately 1 month. The stable isotope amino acids
tracers that will be infused intravenously during the experimental trial are
produced according to GMP standards and are safe for human use. In order to
administer this infusion, a catheter will be placed in an antecubital vein,
this might result in a small local hematoma.
There is no risk associated with the DEXA scan. The radiation dose emitted
during a DEXA scan is 0.001 mSv. This is a very low exposure compared to the
total background radiation in the Netherlands, which is ~2.5 mSv/year.
Universiteitssingel 50
Maastricht 6229 ER
NL
Universiteitssingel 50
Maastricht 6229 ER
NL
Listed location countries
Age
Inclusion criteria
- Male
- Aged18-35 y inclusive
- BMI 18.5 * 27.5 inclusive
- Healthy recreationally active males
Exclusion criteria
- Females
- Wheat allergy
- Celiac disease
- Allergies to milk proteins
- Lactose intolerance
- Smoking
- Diagnosed diabetes
- Diagnosed metabolic or intestinal disorders
- A history of neuromuscular problems
- Any medications known to (or may) affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications).
- Participation in structured resistance exercise program
- Previous participation in a 13C amino acid tracer study within the last 1 year
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
In other registers
| Register | ID |
|---|---|
| CCMO | NL60500.068.17 |
| Other | Protocol will be registered at NTR after approval by the METC |
| OMON | NL-OMON21457 |